In plain language. Written by scientists. For the global HD community.

A well-studied, widely used class of drugs for heart health may have benefits for Huntington’s disease. A new paper ...

Ed is a neurologist at the National Hospital for Neurology and Neurosurgery, London, UK, and a Professor of Neurology at University College London where he is Associate Director of the Huntington’s ...

Michael is a consultant neurologist in the department of neurology at the University of Ulm in Germany, and scientific projects manager for the European Huntington’s disease network. Michael trained ...

Please consider making a donation if you value the services that HDBuzz provides. We want HDBuzz to be sustainable so that we can continue to report unbiased science to the HD community. With your ...

Siddharth is an MD/PhD candidate in Dr. Ray Truant’s lab at McMaster University in Hamilton, Canada. Prior to this, he obtained an Honours Bachelor of Science in Biochemistry, also from McMaster. His ...

Emmy-award winning tv journalist, Charles Sabine, has worked for the us network NBC news for 26 years. That career took him, via twelve wars, six revolutions, and four earthquakes, to most of the news ...

In plain language. Written by scientists. For the global HD community.

Please consider making a donation if you value the services that HDBuzz provides. We want HDBuzz to be sustainable so that we can continue to report unbiased science to the HD community. With your ...

In an update shared today, uniQure announced alignment with the US drug regulator on key criteria for accelerated approval of ...

On December 3, 2024 we received word that the very first person received a new drug, called ALN-HTT02, as part of a Phase 1 trial aiming to treat Huntington’s disease (HD). Going boldly as the first ...